New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in annual sales by 2027 or be clinical “game changers,” according to Clarivate. This year’s list reflects pharma’s increasing focus…
Astellas licenses companion drug for Pompe gene therapy
Astellas has licensed rights to a drug developed by Selecta Biosciences that could make more patients eligible for treatment with its gene therapy for inherited neuromuscular disorder Pompe disease. The exclusive deal – which includes an upfront payment of $10…
NICE backs “artificial pancreas” tech for type 1 diabetics
More than 100,000 people in England and Wales with type 1 diabetes that they find hard to control with current therapy could soon be offered new technology via the NHS. In draft guidance, the NICE committee has recommended the use…
Chiesi expands rare disease portfolio with Amryt Pharma acquisition
Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. in an all-cash transaction at $14.50 per American Depositary Share (ADS). Each ADS represents five Amryt ordinary shares. Supported by voting agreements from leading Amryt…
Novartis licenses cocaine use disorder therapy to Stalicla
Swiss biotech Stalicla has continued to diversify its pipeline from a focus on autism therapies with a deal to license Novartis’ mavoglurant, in clinical trials for cocaine use disorder (CUD) as well as neurodevelopmental disorders (NDD). Geneva-based Stalicla has acquired…
The US as a country has the highest number of trials, followed by China and India – New year, new trials: analysis reveals clinical trial activity trends in 2023
With the start of the new year, GlobalData released a new report providing a glimpse into what to expect in the clinical trial space in 2023. The report reviews clinical trials that are planned to start and complete this year.…
With FDA Accelerated Approval Of Alzheimer’s Drug Lecanemab Likely January 6th, Discussion Turns To Price And Reimbursement
According to the Institute for Clinical and Economic Review (ICER), the beta amyloid-directed monoclonal antibody, lecanemab, must be priced lowerthan $20,600 a year to be cost-effective. Specifically, ICER’s calculations suggest that the Alzheimer’s Disease drug’s demonstrated benefits in a Phase…
Google Cofounder Sergey Brin Has Quietly Donated More Than $1 Billion Toward Parkinson’s Disease
A dozen years ago, Google cofounder Sergey Brin disclosed in a rare interview that he has a much higher chance of getting Parkinson’s disease than the general population, due to a genetic mutation. Since then, without fanfare, Brin—now the world’s…
Meet The Entrepreneur Helping Women In Chemo Keep Their Hair
Kate Dilligan spent $8,000 to save her hair during cancer treatments, then spent another $40,000 to see if there was a better way. There was. COOLER HEADS When 45-year-old Jennifer Graff was diagnosed with breast cancer in August, one of…
